$0.33
5.37% yesterday
Nasdaq, Jun 27, 10:14 pm CET
ISIN
US23254L4059
Symbol
CYCC
Sector
Industry

Cyclacel Pharmaceuticals, Inc. Stock price

$0.33
-1.29 79.57% 1M
-5.34 94.16% 6M
-5.69 94.50% YTD
-26.87 98.78% 1Y
-333.27 99.90% 3Y
-1,113.27 99.97% 5Y
-44,927.67 100.00% 10Y
-2,782,079.67 100.00% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.02 5.37%
ISIN
US23254L4059
Symbol
CYCC
Sector
Industry

Key metrics

Basic
Market capitalization
$7.9m
Enterprise Value
$4.4m
Net debt
$-3.5m
Cash
$3.5m
Shares outstanding
13.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
786.44 | 77.06
EV/Sales
441.44 | 43.24
EV/FCF
negative
P/B
1.40
Financial Health
Equity Ratio
-53.10%
Return on Equity
515.73%
ROCE
-413.19%
ROIC
-9,078.82%
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$10.0k | $102.0k
EBITDA
- | -
EBIT
$-12.7m
Net Income
$-8.4m | $-15.6m
Free Cash Flow
$-10.8m
Growth (TTM | estimate)
Revenue
-97.78% | 155.00%
EBITDA
- | -
EBIT
43.60%
Net Income
57.93% | -39.16%
Free Cash Flow
-10.48%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-90,607.14%
Net
-59,621.43% | -15,292.80%
Free Cash Flow
-76,814.29%
More
EPS
$-0.64
FCF per Share
$-0.83
Short interest
81.68%
Employees
12.00
Rev per Employee
$0.00
Show more

Is Cyclacel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Cyclacel Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cyclacel Pharmaceuticals, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Cyclacel Pharmaceuticals, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Cyclacel Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.01 0.01
98% 98%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.02 8.02
20% 20%
80,200%
- Research and Development Expense 4.68 4.68
71% 71%
46,800%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
44% 44%
-126,850%
Net Profit -8.35 -8.35
58% 58%
-83,500%

In millions USD.

Don't miss a Thing! We will send you all news about Cyclacel Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cyclacel Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale of its convertible Series F Preferred Stock (“Preferred Stock”) in a private placement to certain accredited investors...
Neutral
GlobeNewsWire
25 days ago
KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has received a letter (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) dated June 3, 2025, ...
Neutral
GlobeNewsWire
about one month ago
KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update.
More Cyclacel Pharmaceuticals, Inc. News

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Head office United States
CEO Sing Wong
Employees 12
Founded 1996
Website cyclacel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today